Clinical trial · Observational
A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
A Multi-center Observational Study of the Effectiveness of Elranatamab in Patients With Relapsed and/or Refractory Multiple Myeloma in Taiwan
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate: * What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan? * What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan? * What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Refractory Multiple Myeloma (RRMM) | Multiple Myeloma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non intervention | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Elranatamab in Patients with Relapsed and/or Refractory Multiple Myeloma
- description
- Patients with Relapsed and/or Refractory Multiple Myeloma treated with Elranatamab
- interventionNames
- Drug: Non intervention
Primary outcomes (6)
- measure
- rwTTR (real-world time to response)
- timeFrame
- At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)
- description
- Time from index date to the first documented real-world response.
- measure
- rwORR (real-world overall response rate)
- timeFrame
- At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)
- description
- Proportion of patients achieving real-world overall response at predefined assessment time points.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. Patients age ≥ 18 years at the initiation of elranatamab 2. Patients who have received at least one dose of elranatamab in consistent with the approved label in Taiwan. 3. Evidence of a personally signed and dated informed consent document (ICD) indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. The ICD waiver is acceptable for patient who was ceased before recruitment. Exclusion criteria: Patients who participated in any prior clinical trials using elranatamab.
References
Publications (0)
Data not yet available